Skip to main content

Advertisement

SpringerLink
Log in

Relieve pruritus associated with cholestatic disease by treating the underlying cause and using antipuritic agents

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Kremer AE, Beuers U, Oude-Elferink RPJ, et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68(15): 2163–82

    Article  PubMed  CAS  Google Scholar 

  2. Stander S, Streit M, Darsow U, et al. Diagnostic and therapeutic procedures in chronic pruritus [in German]. J Dtsh Dermatol Ges 2006; 4(4): 350–70

    Article  Google Scholar 

  3. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 Sep; 113(3): 884–90

    Article  PubMed  CAS  Google Scholar 

  4. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336(10): 691–5

    Article  PubMed  CAS  Google Scholar 

  5. Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1(4): 297–302

    Article  PubMed  Google Scholar 

  6. Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998; 26(1): 49–55

    Article  PubMed  CAS  Google Scholar 

  7. Dinler G, Kocak N, Yuce A, et al. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk J Pediatr 1999; 41(1): 91–8

    PubMed  CAS  Google Scholar 

  8. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005 Sep; 129(3): 894–901

    Article  PubMed  CAS  Google Scholar 

  9. Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997 Dec; 27(6): 1022–8

    Article  PubMed  CAS  Google Scholar 

  10. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid: adverse effects and drug interactions. Aliment Pharmacol Ther 2003 Nov 15; 18(10): 963–72

    Article  PubMed  CAS  Google Scholar 

  11. Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on stabile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30(2): 135–9

    Article  PubMed  CAS  Google Scholar 

  12. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006 Oct; 26(8): 943–8

    Article  PubMed  CAS  Google Scholar 

  13. Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102(7): 1528–36

    Article  PubMed  CAS  Google Scholar 

  14. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50(3): 436–9

    Article  PubMed  CAS  Google Scholar 

  15. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297(6662): 1501–4

    Article  PubMed  CAS  Google Scholar 

  16. Carson KL, Tran TT, Cotton P, et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91(5): 1022–3

    PubMed  CAS  Google Scholar 

  17. Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97(8): 2117–9

    Article  PubMed  Google Scholar 

  18. Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists: an effective new possibility for treating chronic pruritus [in German]. Hautarzt 2006; 57(9): 801–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Relieve pruritus associated with cholestatic disease by treating the underlying cause and using antipuritic agents. Drugs Ther. Perspect 25, 20–23 (2009). https://doi.org/10.2165/0042310-200925070-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925070-00006

Search

Navigation